|
Nutra Pharma Corp. (OTCBB: NPHC) is a biopharmaceutical
company specializing in the acquisition, licensing
and commercialization of pharmaceutical products
and technologies for the management of neurological
disorders, cancer, autoimmune and infectious diseases.
 Nutra
Pharma Corp. through its subsidiaries carries
out basic drug discovery research and clinical
development and also seeks strategic licensing
partnerships to reduce the risks associated with
the drug development process. The Company's holding,
ReceptoPharm,
is developing technologies for the production
of drugs for HIV and Multiple Sclerosis ("MS").
The Company's subsidiary,
Designer Diagnostics, is engaged in the research
and development of diagnostic test kits designed
to be used for the rapid identification of infectious
diseases such as Tuberculosis (TB) and Mycobacterium
avium-intracellulare (MAI).
Nutra Pharma continues to identify and acquire
intellectual property and companies in the biotechnology
arena.
Nutra Pharma is dedicated to the success of its
patients, customers, investors and business partners
through its development and acquisition of innovative
pharmaceutical and life science solutions that
will improve the lives of people throughout the
world.
|
